|
|
Vaccine Detail
|
pMUC1/pmuIL-18 DNA Vaccine |
| Vaccine Information |
- Vaccine Name: pMUC1/pmuIL-18 DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Snyder et al., 2006)
-
Adjuvant:
murine IL-18 (Snyder et al., 2006)
- Immunization Route: Intradermal injection (i.d.)
- Description: A bivalent plasmid DNA vaccine consisting of two co-administered plasmids encoding human MUC1 antigen (pMUC1) and murine interleukin-18 adjuvant (pmuIL-18). The pMUC1 plasmid encodes a 508 amino acid human MUC1 protein containing a truncated tandem repeat domain with 6.5 repeats. The two plasmids must be mixed together prior to intradermal injection for therapeutic efficacy; administration of either plasmid alone or at separate sites provides no protection. Vaccination in MUC1 transgenic mice breaks tolerance to MUC1 and induces significant tumor protection (70% tumor-free vs. 0% with single agents, P=0.003) and prolonged survival (>90 days) after subcutaneous challenge with MC38/MUC1 colorectal adenocarcinoma cells. Protection is mediated primarily by CD4+ T cells with contributions from CD8+ T cells. The vaccine induces durable memory responses with 82% of mice protected upon tumor rechallenge 8 weeks later, and promotes epitope spreading with 71% protection against MUC1-negative MC38 tumors. MUC1, a transmembrane glycoprotein normally expressed on ductal epithelia, is overexpressed in hypoglycosylated forms in adenocarcinomas of the breast, prostate, lung, colon, ovary, and pancreas (Snyder et al., 2006).
|
| Host Response |
|
|
| References |
Snyder et al., 2006: Snyder LA, Goletz TJ, Gunn GR, Shi FF, Harris MC, Cochlin K, McCauley C, McCarthy SG, Branigan PJ, Knight DM. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine. 2006; 24(16); 3340-3352. [PubMed: 16472547].
|
|
